About this trial
Gout is characterized by episodes of acute arthritis of the lower limbs due to intermittent activation of innate immunity in the joints where urate crystals have formed. These crystals occur when serum urate (SUA) levels have been above 70 mg/L for many years. They can be dissolved by lowering SUA levels to at least 60 mg/L (treat-to-target - T2T - strategy). Once the crystals are dissolved, patients are no longer symptomatic and are considered to be in remission (treat-to-dissolve - T2D - strategy).
The presence of crystals and their dissolution during treatment can be monitored by repeated ultrasound (US) scans of the feet and knees.
The time required for complete dissolution varies from patient to patient. ReViGore40 is a cohort designed to i) determine the time to complete dissolution of urate deposits in joints when SUA levels are maintained below 40 mg/L, ii) determine the factors (clinical, biological, genetic) associated with the time required for complete dissolution of urate deposits within joints.
Eligibility criteria
Qualifiers
Age over 18 years
Gout according to the ACR/Eular 2015 criteria
SUA levels greater than 60 mg/L
US score (MTP1s, knees) ≥2/24
Disqualifiers
Ongoing urate lowering therapy
Severe and uncontrolled diseases such as cancer, cardiovascular or neurovegetative diseases
Pregnant or breast-feeding women
No affiliation to the French National Social Security System
Trial design
Treatments tested in this trial
- Standard X-Rays
- Ultrasound
- DECT of feet
- DNA sample
- Serum collection
Treatment groups
Sponsors and collaborators
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborator
ART VIGGO Association for Research
Collaborator